Seres Therapeutics (MCRB) Competitors $0.97 +0.05 (+5.60%) (As of 01:03 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends MCRB vs. ORIC, TERN, VECT, TRML, PHAT, PROK, ATXS, DNA, ANNX, and HUMAShould you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include ORIC Pharmaceuticals (ORIC), Terns Pharmaceuticals (TERN), VectivBio (VECT), Tourmaline Bio (TRML), Phathom Pharmaceuticals (PHAT), ProKidney (PROK), Astria Therapeutics (ATXS), Ginkgo Bioworks (DNA), Annexon (ANNX), and Humacyte (HUMA). These companies are all part of the "pharmaceutical products" industry. Seres Therapeutics vs. ORIC Pharmaceuticals Terns Pharmaceuticals VectivBio Tourmaline Bio Phathom Pharmaceuticals ProKidney Astria Therapeutics Ginkgo Bioworks Annexon Humacyte ORIC Pharmaceuticals (NASDAQ:ORIC) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends. Does the media favor ORIC or MCRB? In the previous week, ORIC Pharmaceuticals had 9 more articles in the media than Seres Therapeutics. MarketBeat recorded 11 mentions for ORIC Pharmaceuticals and 2 mentions for Seres Therapeutics. ORIC Pharmaceuticals' average media sentiment score of 0.46 beat Seres Therapeutics' score of 0.45 indicating that ORIC Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ORIC Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Seres Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer ORIC or MCRB? Seres Therapeutics received 468 more outperform votes than ORIC Pharmaceuticals when rated by MarketBeat users. However, 72.09% of users gave ORIC Pharmaceuticals an outperform vote while only 72.01% of users gave Seres Therapeutics an outperform vote. CompanyUnderperformOutperformORIC PharmaceuticalsOutperform Votes6272.09% Underperform Votes2427.91% Seres TherapeuticsOutperform Votes53072.01% Underperform Votes20627.99% Which has more volatility & risk, ORIC or MCRB? ORIC Pharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Do analysts rate ORIC or MCRB? ORIC Pharmaceuticals presently has a consensus target price of $18.29, suggesting a potential upside of 119.52%. Seres Therapeutics has a consensus target price of $5.08, suggesting a potential upside of 438.55%. Given Seres Therapeutics' higher possible upside, analysts clearly believe Seres Therapeutics is more favorable than ORIC Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ORIC Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Seres Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Do insiders and institutionals hold more shares of ORIC or MCRB? 95.1% of ORIC Pharmaceuticals shares are held by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are held by institutional investors. 5.6% of ORIC Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Seres Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has higher earnings and valuation, ORIC or MCRB? ORIC Pharmaceuticals has higher earnings, but lower revenue than Seres Therapeutics. ORIC Pharmaceuticals is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioORIC PharmaceuticalsN/AN/A-$100.70M-$1.80-4.63Seres Therapeutics$126.32M1.28-$113.72M-$0.23-4.10 Is ORIC or MCRB more profitable? Seres Therapeutics' return on equity of 0.00% beat ORIC Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ORIC PharmaceuticalsN/A -42.47% -38.86% Seres Therapeutics N/A N/A -55.08% SummaryORIC Pharmaceuticals beats Seres Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Insiders ExposedMysterious drone activity triggers massive 1,366% surgeIf mysterious drones buzzing over the East Coast weren’t on your radar this year, you’re not alone. But here’s what you really need to know: An early warning signal tipped off investors to a tiny drone stock that later skyrocketed 1,366%.👉 Click here now to see how this signal works. Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MCRB vs. The Competition Export to ExcelMetricSeres TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$161.16M$6.61B$5.16B$9.10BDividend YieldN/A2.99%5.12%4.26%P/E Ratio-4.1010.6387.5117.12Price / Sales1.28194.281,136.45119.65Price / CashN/A57.1643.2337.85Price / Book-2.705.104.784.77Net Income-$113.72M$151.83M$120.55M$225.50M7 Day Performance6.06%-1.19%-1.64%-1.29%1 Month Performance22.81%-4.73%14.04%0.45%1 Year Performance-25.68%8.89%28.88%15.38% Seres Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MCRBSeres Therapeutics3.3551 of 5 stars$0.97+5.6%$5.08+425.8%-27.9%$165.07M$126.32M-4.20233Positive NewsORICORIC Pharmaceuticals3.6875 of 5 stars$8.45-0.8%$18.29+116.4%-7.5%$596.32MN/A-4.6880News CoverageTERNTerns Pharmaceuticals4.2551 of 5 stars$6.97+3.6%$18.30+162.6%-10.7%$592.03M$1M-5.7040Positive NewsVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030TRMLTourmaline Bio2.3325 of 5 stars$22.34+2.4%$54.00+141.7%-12.5%$572.87MN/A-7.7344PHATPhathom Pharmaceuticals3.0076 of 5 stars$8.35+5.8%$23.00+175.4%-17.3%$570.97M$680,000.00-1.48110Gap UpPROKProKidney2.0497 of 5 stars$1.93+7.2%$4.50+133.8%-25.6%$561.45MN/A-3.553Gap UpATXSAstria Therapeutics2.0614 of 5 stars$9.78+2.7%$25.60+161.8%+40.8%$551.89MN/A-4.5630DNAGinkgo Bioworks0.7565 of 5 stars$9.50+0.6%$4.58-51.8%N/A$546.06M$251.46M-0.721,218ANNXAnnexon2.1164 of 5 stars$5.12+15.3%$15.80+208.6%+30.4%$545.76MN/A-4.9060HUMAHumacyte3.366 of 5 stars$4.23+3.2%$13.00+207.3%+61.1%$532.38M$1.57M-3.06150Analyst ForecastGap Up Related Companies and Tools Related Companies ORIC Competitors TERN Competitors VECT Competitors TRML Competitors PHAT Competitors PROK Competitors ATXS Competitors DNA Competitors ANNX Competitors HUMA Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:MCRB) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MCRB Stock Alerts